In 2001, Dr. Francisco M. Martin-Saavedra joined the Spanish National Center of Microbiology to develop his PhD studies in multiple sclerosis (MS) therapeutics. In 2006, he obtained his PhD from the School of Biological Sciences of the Universidad Complutense de Madrid and continued his postdoctoral research focused in MS immunology. In 2007, he joined the University Hospital La Paz-IdiPAZ (HULP-IdiPAZ) and the Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) for studies focused in gene therapy and nanomedicine. In 2011, Dr. Martín-Saavedra joined the University of Michigan-USA for continue his studies on controlled delivery of growth factors for bone tissue engineering. In late 2013, he joined as a senior researcher of CIBER-BBN at HULP-IdiPAZ.